Payment overview · 2025
General Payments
$205.95
10 reported records · 7 companies
Healthcare provider profile · identity verified
Jerry Von Thomas, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CAPE CORAL, FL · NPI 1891777090
Verified facts
What the public records show
CMS Open Payments records show Jerry Von Thomas, M.D. received $205.95 in general payments during 2025 across 10 reported records.
CorVista Health, Inc. accounted for 31.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| CorVista Health, Inc. | Unresolved — no canonical attribution shown | $63.86 | 31.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $34.73 | 16.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.73 | 15.4% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $26.62 | 12.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $19.66 | 9.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.65 | 8.1% | 1 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $12.70 | 6.2% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $205.95 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CorVista System Normalized: corvista system |
Device | CorVista Health, Inc. | $63.86 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $34.73 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $31.73 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $26.62 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $26.62 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $12.70 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 86 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
86 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
127 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 941 | 277 |
| Levothyroxine Sodium | Levothyroxine Sodium | 794 | 210 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 669 | 199 |
| Amlodipine Besylate | Amlodipine Besylate | 626 | 186 |
| Losartan Potassium | Losartan Potassium | 588 | 176 |
| Lisinopril | Lisinopril | 499 | 149 |
| Alprazolam | Alprazolam | 489 | 100 |
| Metformin Hcl | Metformin Hcl | 481 | 148 |
| Metoprolol Succinate | Metoprolol Succinate | 410 | 116 |
| Simvastatin | Simvastatin | 385 | 108 |
| Lovastatin | Lovastatin | 364 | 101 |
| Metoprolol Tartrate | Metoprolol Tartrate | 360 | 104 |
| Tamsulosin Hcl | Tamsulosin Hcl | 333 | 99 |
| Omeprazole | Omeprazole | 309 | 97 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 288 | 87 |
| Gabapentin | Gabapentin | 284 | 86 |
| Zolpidem Tartrate | Zolpidem Tartrate | 283 | 67 |
| Tramadol Hcl | Tramadol Hcl | 265 | 66 |
| Allopurinol | Allopurinol | 264 | 73 |
| Meloxicam | Meloxicam | 263 | 80 |
| Potassium Chloride | Potassium Chloride | 243 | 80 |
| Montelukast Sodium | Montelukast Sodium | 239 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 236 | 83 |
| Hydrochlorothiazide | Hydrochlorothiazide | 234 | 67 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 219 | 89 |
| Trazodone Hcl | Trazodone Hcl | 209 | 61 |
| Eliquis | Apixaban | 183 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 180 | 50 |
| Citalopram Hbr | Citalopram Hydrobromide | 177 | 53 |
| Furosemide | Furosemide | 174 | 60 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 171 | 52 |
| Ezetimibe | Ezetimibe | 167 | 50 |
| Lorazepam | Lorazepam | 146 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 145 | 43 |
| Atenolol | Atenolol | 144 | 41 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 144 | 33 |
| Torsemide | Torsemide | 144 | 53 |
| Glipizide Er | Glipizide | 142 | 41 |
| Temazepam | Temazepam | 135 | 24 |
| Trulicity | Dulaglutide | 127 | 19 |
| Clonazepam | Clonazepam | 126 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 121 | 34 |
| Alendronate Sodium | Alendronate Sodium | 119 | 35 |
| Fenofibrate | Fenofibrate | 116 | 32 |
| Ibuprofen | Ibuprofen | 109 | 30 |
| Methylprednisolone | Methylprednisolone | 108 | 84 |
| Finasteride | Finasteride | 105 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 104 | 38 |
| Celecoxib | Celecoxib | 98 | 31 |
| Famotidine | Famotidine | 96 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 96 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 95 | 80 |
| Synthroid | Levothyroxine Sodium | 94 | 24 |
| Carvedilol | Carvedilol | 93 | 26 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 89 | 60 |
| Sumatriptan Succinate | Sumatriptan Succinate | 89 | 21 |
| Xarelto | Rivaroxaban | 88 | 21 |
| Mounjaro | Tirzepatide | 86 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 85 | 24 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 84 | 24 |
| Sertraline Hcl | Sertraline Hcl | 81 | 23 |
| Benazepril Hcl | Benazepril Hcl | 78 | 22 |
| Spironolactone | Spironolactone | 75 | 26 |
| Azithromycin | Azithromycin | 74 | 67 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 73 | 53 |
| Bupropion Xl | Bupropion Hcl | 72 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 72 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 71 | 23 |
| Warfarin Sodium | Warfarin Sodium | 68 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 26 |
| Diazepam | Diazepam | 66 | 17 |
| Januvia | Sitagliptin Phosphate | 66 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | 16 |
| Gemfibrozil | Gemfibrozil | 63 | 18 |
| Labetalol Hcl | Labetalol Hcl | 61 | 13 |
| Glimepiride | Glimepiride | 60 | 17 |
| Baclofen | Baclofen | 58 | 18 |
| Clonidine Hcl | Clonidine Hcl | 58 | 16 |
| Prednisone | Prednisone | 55 | 22 |
| Raloxifene Hcl | Raloxifene Hcl | 55 | 12 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 51 | 17 |
| Glipizide | Glipizide | 50 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 30 |
| Donepezil Hcl | Donepezil Hcl | 49 | 19 |
| Pregabalin | Pregabalin | 49 | 12 |
| Valacyclovir | Valacyclovir Hcl | 49 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | 11 |
| Jardiance | Empagliflozin | 48 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 16 |
| Estradiol | Estradiol | 45 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 42 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 41 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | suppressed |
| Ondansetron Odt | Ondansetron | 39 | 25 |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | suppressed |
| Nifedipine Er | Nifedipine | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 35 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Klor-Con M20 | Potassium Chloride | 33 | 12 |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Verapamil Er | Verapamil Hcl | 32 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 31 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Ramipril | Ramipril | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 25 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 30 | suppressed |
| Linzess | Linaclotide | 30 | 13 |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Digoxin | Digoxin | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Methotrexate | Methotrexate Sodium | 27 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 25 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Jantoven | Warfarin Sodium | 24 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 24 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Anastrozole | Anastrozole | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Ozempic | Semaglutide | 20 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 19 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 13 |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 12 |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 12 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $205.95 · 10 records | CorVista Health, Inc. | Barostim Neo System, CAPVAXIVE, CorVista System, Dexcom G6 Transmitter, EVENITY, GARDASIL 9, MOUNJARO, Veozah, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error